797 related articles for article (PubMed ID: 30552159)
1. Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas.
Merli M; Frigeni M; Alric L; Visco C; Besson C; Mannelli L; Di Rocco A; Ferrari A; Farina L; Pirisi M; Piazza F; Loustaud-Ratti V; Arcari A; Marino D; Sica A; Goldaniga M; Rusconi C; Gentile M; Cencini E; Benanti F; Rumi MG; Ferretti VV; Grossi P; Gotti M; Sciarra R; Tisi MC; Cano I; Zuccaro V; Passamonti F; Arcaini L
Oncologist; 2019 Aug; 24(8):e720-e729. PubMed ID: 30552159
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of new direct antiviral agents in hepatitis C virus-infected patients with diffuse large B-cell non-Hodgkin's lymphoma.
Persico M; Aglitti A; Caruso R; De Renzo A; Selleri C; Califano C; Abenavoli L; Federico A; Masarone M
Hepatology; 2018 Jan; 67(1):48-55. PubMed ID: 28714143
[TBL] [Abstract][Full Text] [Related]
3. Impact of treatment-related toxicity on outcome of HCV-positive diffuse large B-cell lymphoma in rituximab era.
Zaky AH; Bakry R; El-sayed MI; Elwanis MA; Nabih O
Hematology; 2014 Oct; 19(7):412-6. PubMed ID: 24620947
[TBL] [Abstract][Full Text] [Related]
4. Direct-acting antivirals in relapsed or refractory hepatitis C virus-associated diffuse large B-cell lymphoma.
Merli M; Defrancesco I; Visco C; Besson C; Di Rocco A; Arcari A; Sica A; Cencini E; Tisi MC; Frigeni M; Grossi P; Bianchi B; Mora B; Bertù L; Bruno R; Passamonti F; Arcaini L
Leuk Lymphoma; 2020 Sep; 61(9):2122-2128. PubMed ID: 32343165
[TBL] [Abstract][Full Text] [Related]
5. Concomitant therapy with direct-acting antivirals and chemoimmunotherapy in HCV-associated diffuse large B-cell lymphoma.
Occhipinti V; Farina L; Viganò M; Capecchi M; Labanca S; Fanetti I; Corradini P; Rumi M
Dig Liver Dis; 2019 May; 51(5):719-723. PubMed ID: 30502232
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and prognosis of antiviral therapy on hepatitis C following treatment of lymphoma in HCV-positive diffuse large-cell lymphoma.
Tsutsumi Y; Nakayama C; Kamada K; Kikuchi R; Kudo D; Ito S; Matsuoka S; Shiratori S; Yamamoto Y; Naruse H; Teshima T
Ann Hematol; 2017 Dec; 96(12):2057-2061. PubMed ID: 28939993
[TBL] [Abstract][Full Text] [Related]
7. Biological features and outcome of diffuse large B-cell lymphoma associated with hepatitis C virus in elderly patients: Results of the prospective 'Elderly Project' by the Fondazione Italiana Linfomi.
Arcari A; Tabanelli V; Merli F; Marcheselli L; Merli M; Balzarotti M; Zilioli VR; Fabbri A; Cavallo F; Casaluci GM; Tucci A; Puccini B; Pennese E; Di Rocco A; Zanni M; Flenghi L; Gini G; Sartori R; Chiappella A; Usai SV; Tani M; Marino D; Arcaini L; Vallisa D; Spina M
Br J Haematol; 2023 May; 201(4):653-662. PubMed ID: 36733229
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis C virus and diffuse large B-cell lymphoma: Pathogenesis, behavior and treatment.
Visco C; Finotto S
World J Gastroenterol; 2014 Aug; 20(32):11054-61. PubMed ID: 25170194
[TBL] [Abstract][Full Text] [Related]
9. Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial.
Johnston PB; LaPlant B; McPhail E; Habermann TM; Inwards DJ; Micallef IN; Colgan JP; Nowakowski GS; Ansell SM; Witzig TE
Lancet Haematol; 2016 Jul; 3(7):e309-16. PubMed ID: 27374464
[TBL] [Abstract][Full Text] [Related]
10. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial.
Huang H; Li X; Zhu J; Ye S; Zhang H; Wang W; Wu X; Peng J; Xu B; Lin Y; Cao Y; Li H; Lin S; Liu Q; Lin T
JAMA; 2014 Dec; 312(23):2521-30. PubMed ID: 25514302
[TBL] [Abstract][Full Text] [Related]
11. Successful treatment by on-demand glecaprevir and pibrentasvir for hepatitis C flare during R-CHOP in patients with diffuse large B-cell lymphoma: a case report.
Umemura M; Suda G; Tsukamoto S; Ebata K; Takahash S; Sasaki T; Nakajima S; Hirata K; Ozasa M; Takano M; Katagiri M; Sakamoto N
BMC Infect Dis; 2021 Apr; 21(1):389. PubMed ID: 33906643
[TBL] [Abstract][Full Text] [Related]
12. Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.
Thieblemont C; Tilly H; Gomes da Silva M; Casasnovas RO; Fruchart C; Morschhauser F; Haioun C; Lazarovici J; Grosicka A; Perrot A; Trotman J; Sebban C; Caballero D; Greil R; van Eygen K; Cohen AM; Gonzalez H; Bouabdallah R; Oberic L; Corront B; Choufi B; Lopez-Guillermo A; Catalano J; Van Hoof A; Briere J; Cabeçadas J; Salles G; Gaulard P; Bosly A; Coiffier B
J Clin Oncol; 2017 Aug; 35(22):2473-2481. PubMed ID: 28426350
[TBL] [Abstract][Full Text] [Related]
13. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
[TBL] [Abstract][Full Text] [Related]
14. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcome of HCV-positive patients with diffuse large B-cell lymphoma treated with rituximab-based chemotherapy.
Salah-Eldin MA; Ebrahim MA; El-Sadda W
Ann Hematol; 2014 Nov; 93(11):1903-11. PubMed ID: 24951125
[TBL] [Abstract][Full Text] [Related]
16. Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients.
Park YH; Lee JJ; Ryu MH; Kim SY; Kim DH; Do YR; Lee KH; Oh SJ; Kim YK; Suh CW; Heo DS; Ryoo BY; Kim JK; Song HS; Lee WS; Kim HJ; Bang YJ; Yang SH; Sohn SK; Kang YK;
Ann Hematol; 2006 Apr; 85(4):257-62. PubMed ID: 16416337
[TBL] [Abstract][Full Text] [Related]
17. Prophylactic antiviral therapy for hepatitis B virus surface antigen-positive patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy.
Yamauchi N; Maruyama D; Choi I; Atsuta Y; Sakai R; Miyashita K; Moriuchi Y; Tsujimura H; Kubota N; Yamamoto G; Igarashi T; Izutsu K; Yoshida S; Kojima K; Uchida T; Inoue Y; Tsukamoto N; Ohtsuka E; Suzuki S; Inaguma Y; Ichikawa S; Gomyo H; Ushijima Y; Nosaka K; Kurata M; Tanaka Y; Ueda R; Mizokami M; Kusumoto S
Cancer Sci; 2021 May; 112(5):1943-1954. PubMed ID: 33576088
[TBL] [Abstract][Full Text] [Related]
18. [Recurrence of malignant lymphoma immediately after treatment for hepatitis C virus using direct-acting antivirals].
Iwane K; Kayahara T; Takabatake H; Morimoto Y; Iseki A; Mizuno M; Notohara K
Nihon Shokakibyo Gakkai Zasshi; 2019; 116(2):177-183. PubMed ID: 30745556
[TBL] [Abstract][Full Text] [Related]
19. Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis.
Ennishi D; Maeda Y; Niitsu N; Kojima M; Izutsu K; Takizawa J; Kusumoto S; Okamoto M; Yokoyama M; Takamatsu Y; Sunami K; Miyata A; Murayama K; Sakai A; Matsumoto M; Shinagawa K; Takaki A; Matsuo K; Kinoshita T; Tanimoto M
Blood; 2010 Dec; 116(24):5119-25. PubMed ID: 20823454
[TBL] [Abstract][Full Text] [Related]
20. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy.
Phan J; Mazloom A; Medeiros LJ; Zreik TG; Wogan C; Shihadeh F; Rodriguez MA; Fayad L; Fowler N; Reed V; Horace P; Dabaja BS
J Clin Oncol; 2010 Sep; 28(27):4170-6. PubMed ID: 20713859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
